MilliDrop, a Paris, France-based company that designs and develops cell culture solutions based on millifluidics technology for bacteriological research and diagnosis purposes, has been awarded €1.9 million in non-dilutive financing.
Bpifrance provided the award.
Millidrop received this funding as a laureate of the “Concours d’Innovation” (Innovation Challenge) in the health category with its project “Droplet-Based Integrated Diagnosis from Blood Culture to Antibiogram”, that was backed by the Medicen Paris Région competitiveness cluster.
Led by Yamina Ghomchi, CEO, the company leverages millifluidic technologies to develop and market systems for microbiology applications that incubate, analyze and handle thousands of hundred-nanoliter-scale samples in parallel. Its compact system seamlessly complements other laboratory instruments, including automated screening platforms. Its miniaturization to the millimeter scale delivers a 1,000-fold leap in productivity.
MilliDrop now intends to use the funds to accelerate the development of its blood infection diagnosis system for sepsis.